Sampa Santra, Georgia D Tomaras, Ranjit Warrier, Nathan I Nicely, Hua-Xin Liao, Justin Pollara, Pinghuang Liu, S Munir Alam, Ruijun Zhang, Sarah L Cocklin, Xiaoying Shen, Ryan Duffy, Shi-Mao Xia, Robert J Schutte, Charles W Pemble Iv, S Moses Dennison, Hui Li, Andrew Chao, Kora Vidnovic, Abbey Evans, Katja Klein, Amit Kumar, James Robinson, Gary Landucci, Donald N Forthal, David C Montefiori, Jaranit Kaewkungwal, Sorachai Nitayaphan, Punnee Pitisuttithum, Supachai Rerks-Ngarm, Merlin L Robb, Nelson L Michael, Jerome H Kim, Kelly A Soderberg, Elena E Giorgi, Lily Blair, Bette T Korber, Christiane Moog, Robin J Shattock, Norman L Letvin, Joern E Schmitz, M A Moody, Feng Gao, Guido Ferrari, George M Shaw, Barton F Haynes
HIV-1 mucosal transmission begins with virus or virus-infected cells moving through mucus across mucosal epithelium to infect CD4+ T cells. Although broadly neutralizing antibodies (bnAbs) are the type of HIV-1 antibodies that are most likely protective, they are not induced with current vaccine candidates. In contrast, antibodies that do not neutralize primary HIV-1 strains in the TZM-bl infection assay are readily induced by current vaccine candidates and have also been implicated as secondary correlates of decreased HIV-1 risk in the RV144 vaccine efficacy trial...
August 2015: PLoS Pathogens